Cognition Therapeutics, Inc. (CGTX)Healthcare | Biotechnology | Purchase, United States | NasdaqCM
0.78 USD
-0.03
(-3.118%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 0.77 0.00 (-0.002%) ⇩ (Oct. 14, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 8:29 a.m. EDT
The immediate outlook is neutral despite a recent surge in the stock price, which erased nearly four years of losses in a single year. While the company recently secured significant regulatory wins regarding its pivotal trial for Lewy Body Dementia and received a 'Strong Buy' recommendation from analysts, these are binary catalysts rather than a guaranteed path to profitability. The balance sheet remains precarious with substantial negative free cash flow and negative earnings, meaning the recent rally is likely driven by speculative positioning on trial results rather than sustainable operational performance. For the short term, the stock is trading near its 50-day moving average, suggesting the recent momentum may be stabilizing but not yet confirming a robust trend. Long-term, the investment case hinges entirely on the success of the upcoming Phase 3 data readout; without a successful trial, the company faces dilution risks typical of biotech firms in this stage. There is no dividend income to offset the high volatility and fundamental risks. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.046938 |
| MSTL | 0.060497 |
| AutoARIMA | 0.063351 |
| AutoETS | 0.063353 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.902 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.784 |
| Market Cap | 73,859,312 |
| Forward P/E | -3.53 |
| Beta | 1.80 |
| Website | https://www.cogrx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5754098 |
| Address1 | 2,500 Westchester Ave. |
| All Time High | 13.8 |
| All Time Low | 0.222 |
| Ask | 0.8002 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 741,050 |
| Average Daily Volume3 Month | 520,973 |
| Average Volume | 520,973 |
| Average Volume10Days | 741,050 |
| Beta | 1.8 |
| Bid | 0.6479 |
| Bid Size | 2 |
| Book Value | 0.347 |
| City | Purchase |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.7767 |
| Current Ratio | 7.027 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.8147 |
| Day Low | 0.77 |
| Debt To Equity | 1.784 |
| Display Name | Cognition Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,742,472,000 |
| Earnings Call Timestamp Start | 1,742,472,000 |
| Earnings Timestamp End | 1,762,977,600 |
| Earnings Timestamp Start | 1,762,977,600 |
| Ebitda | -36,551,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.106 |
| Enterprise Value | 40,436,312 |
| Eps Current Year | -0.29667 |
| Eps Forward | -0.22 |
| Eps Trailing Twelve Months | -0.17 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.98634 |
| Fifty Day Average Change | -0.20963997 |
| Fifty Day Average Change Percent | -0.21254331 |
| Fifty Two Week Change Percent | -57.54098 |
| Fifty Two Week High | 2.0 |
| Fifty Two Week High Change | -1.2233 |
| Fifty Two Week High Change Percent | -0.61165 |
| Fifty Two Week Low | 0.55 |
| Fifty Two Week Low Change | 0.22670001 |
| Fifty Two Week Low Change Percent | 0.41218182 |
| Fifty Two Week Range | 0.55 - 2.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,633,699,800,000 |
| Float Shares | 87,509,069 |
| Forward Eps | -0.22 |
| Forward P E | -3.5304546 |
| Free Cashflow | -23,952,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 14 |
| Fullday Change | -0.011699975 |
| Fullday Change Percent | -1.4593956 |
| Fullday Price | 0.7767 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01289 |
| Held Percent Institutions | 0.23775 |
| Implied Shares Outstanding | 95,093,746 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York. |
| Long Name | Cognition Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 73,859,312 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_39366358 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -16,775,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 93,315,492 |
| Number Of Analyst Opinions | 3 |
| Open | 0.8001 |
| Operating Cashflow | -17,683,000 |
| Operating Margins | 0.0 |
| Phone | 412 481 2210 |
| Post Market Change | -0.0024999976 |
| Post Market Change Percent | -0.3218743 |
| Post Market Price | 0.7742 |
| Post Market Time | 1,792,022,382 |
| Previous Close | 0.8017 |
| Price Eps Current Year | -2.6180606 |
| Price Hint | 4 |
| Price To Book | 2.2383285 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.782 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.025 |
| Regular Market Change Percent | -3.11837 |
| Regular Market Day High | 0.8147 |
| Regular Market Day Low | 0.77 |
| Regular Market Day Range | 0.77 - 0.8147 |
| Regular Market Open | 0.8001 |
| Regular Market Previous Close | 0.8017 |
| Regular Market Price | 0.7767 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 520,828 |
| Return On Assets | -0.78183 |
| Return On Equity | -0.83764 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 95,093,746 |
| Shares Percent Shares Out | 0.0797 |
| Shares Short | 7,579,141 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 7,861,016 |
| Short Name | Cognition Therapeutics, Inc. |
| Short Percent Of Float | 0.086 |
| Short Ratio | 18.88 |
| Source Interval | 15 |
| State | NY |
| Symbol | CGTX |
| Target High Price | 4.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 3.33333 |
| Target Median Price | 3.0 |
| Total Cash | 34,012,000 |
| Total Cash Per Share | 0.358 |
| Total Debt | 589,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.108295 |
| Two Hundred Day Average Change | -0.33159494 |
| Two Hundred Day Average Change Percent | -0.29919377 |
| Type Disp | Equity |
| Volume | 520,828 |
| Website | https://www.cogrx.com |
| Zip | 10,577 |